Connect with us


Should You Worry About This Threat to Moderna’s Vaccine? – Motley Fool

The question is whether it will hurt future revenue — or not.



Article feature image

Moderna’s (NASDAQ:MRNA) success story is all about its coronavirus vaccine. The product generated a whopping $1.7 billion in revenue in the first quarter and brought the company its first ever quarter of profitability. This is big — especially considering Moderna didn’t have any commercialized products until regulators authorized the vaccine in late December.
Investors are hoping this is just the beginning of Moderna’s coronavirus vaccine revenue growth. It should be. Experts say the virus is here…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
New Alzheimer’s drug sparks backlash over FDA, pricing | TheHill – The Hill
Article feature image
Mass. city holds ‘Vaccine Block Party’ to help boost its rates – WCVB Boston
Article feature image
Auction winner bids $28M to fly into space with Jeff Bezos – New York Post